Código QR (código de barras bidimensional)

Clinical evaluation of rituximab combined with ACE inhibitors and statins in refractory nephrotic syndrome: associations with proteinuria, lipid profiles, and podocyte-related biomarkers

BackgroundIn refractory nephrotic syndrome (RNS) poorly responsive to standard therapy, combining rituximab (RTX) with Angiotensin-converting enzyme inhibitors (ACEI) and statins shows synergistic potential, yet its efficacy and podocyte effects require confirmation.ObjectiveTo assess RTX plus ACEI...

ver descrição completa

Na minha lista:
Principais autores: Mengmeng Zhuang, Minguo Chen
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2026-07-01
coleção:Frontiers in Pharmacology
Assuntos:
blood lipid profile
podocytes
proteinuria
refractory nephrotic syndrome
rituximab
statins
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fphar.2026.1851207/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados